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The role of heparin-releasable hepatic endothelial lipase (HL) in human plasma lipoprotein metabolism 
was investigated by examining the effects of intravenous infusion of heparin (180 units/kg over 2 h) in 8 
subjects with primary extrahepatic lipoprotein lipase deficiency. In addition to reducing the triglyceride 
concentration in very low-density lipoproteins, heparin-induced release of HL reduced the phopholipid and 
protein concentrations in the HDL2 subclass of high-density lipoprotein (by 28% and 36% respectively, 
mean values) and simultaneously increased the HDL3 phospholipid concentration (by 23%), providing the 
first in vivo evidence for a function of HL in the interconversion of the major HDL subfractions in man. 
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1. INTRODUCTION 
Chylomicrons and very low-density lipoproteins 
(VLDL) are catabolised through a cascade from 
large to small particles by mechanisms involving 
the heparin-releasable nzyme, lipoprotein lipase 
(LPL), present largely in adipose tissue and 
skeletal muscle [l]. The enzyme requires a specific 
co-factor, apoprotein (apo) C-II 121, and is in- 
hibited by protamine sulphate and 1 .OM NaCl. 
The fractional rate of catabolism of VLDL in man 
is closely correlated with the activity of LPL in 
adipose tissue [3], and familial deficiency of the en- 
zyme [4], or of apoC-II [S] produces severe hyper- 
triglyceridaemia on an uncontrolled diet. In vitro, 
incubation of VLDL with LPL in the presence of 
the HDLs subfraction of high-density lipoprotein 
(HDL) results in the appearance of particles of 
similar density and size to the HDL2 subclass [6], 
due apparently to the transfer of surface 
cholesterol, phospholipid and C apoproteins to 
HDL3. Evidence from studies in vivo also suggests 
that the lipolysis of VLDL and chylomicrons 
results in the transfer of surface material to HDL 
PI. 
Less is known about the functions of hepatic en- 
dothelial lipase (HL). It is also released into the cir- 
culation by intravenous (i.v.) heparin, but does not 
require apoC-II and is not inhibited by 1 .O M NaCl 
[I 1. Two functions have been suggested for the 
enzyme: 
(1) It has been implicated in the catabolism of the 
‘remnants’ of chylomicrons and VLDL. This is 
supported by the accumulation of remnants in 
rats after hepatectomy [7] and after the injec- 
tion of an antibody to HL [8]. Furthermore, 
the triglyceride of VLDL remnants has been 
shown to be a better substrate for the enzyme 
in vitro than the triglyceride of chylomicrons or 
VLDL [9]. On the other hand, Reardon et al. 
[IO] found that the fractional catabolic rate of 
VLDL remnants in man was unrelated to the 
activity of HL in post-heparin plasma. 
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(2) The catabolism of HDLz. Oxandrolone, an 
anabolic steroid, has been shown to elevate 
post-heparin plasma HL activity and to 
simultaneously decrease the concentration of 
HDL;? in man [ 111. Females have lower HL ac- 
tivity and higher HDL2 concentrations than 
men [ 121, and negative correlations between 
HL activity in post-heparin plasma and the 
concentrations of HDL2 lipid and protein com- 
ponents have been reported in healthy men 
[ 131. In addition, there have been recent reports 
that injection of antibody to HL into rats in- 
creases the HDL2 phospholipid concentration 
[14-161. 
In order to clarify the role of HL in man, we 
have studied the changes in plasma lipoproteins 
which are associated with the release of the enzyme 
into plasma during a 2 h intravenous infusion of 
heparin in subjects with documented primary LPL 
deficiency. The results have provided evidence for 
a role of HL both in the catabolism of VLDL and 
in the interconversion of HDL2 to HDL3. 
2. MATERIALS AND METHODS 
2.1. Subjects 
Eight adults with primary LPL deficiency were 
studied. In each subject absence of the enzyme 
from needle biopsies of gluteal adipose tissue 
(heparin-elutable) and/or from post-heparin 
plasma (60 units heparin/kg) had been 
demonstrated as in [5]. At the time of referal to the 
Lipid Clinic of St. Thomas’ Hospital, plasma 
triglyceride concentrations were 7.3-37.2 mmol/l. 
Five normolipidaemic healthy subjects, all with 
normal LPL activity in post-heparin plasma, were 
also studied. 
2.2. Clinical procedures 
Heparin infusions were carried out in a 
metabolic ward, the subjects having fasted for 14 h 
overnight. Each LPL-deficient subject had con- 
sumed a low-fat diet (< 5 g fat/day) for 2-4 days 
before admission to the ward, and all had been 
following a diet containing <2Og fat/day for 
several weeks prior to admission. At the time of the 
study 5 patients (no. l-5) were without fasting 
chylomicronaemia; in the remaining 3 patients (no. 
6-8) chylomicrons were still present in plasma at 
the start of the heparin infusion. 
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After obtaining a baseline venous blood sample 
(20 ml; anticoagulated with 1 mg Na2 EDTA/ml), a 
bolus i.v. injection of heparin, 60units/kg, was 
given. A constant i.v. infusion of heparin was then 
commenced at the rate of 60 units. kg-’ . h-* [5]. 
Blood samples were collected into ice-cold glass 
tubes 10, 30, 60,90 and 120min after the bolus in- 
jection. They were promptly centrifuged at 0-4”C, 
and the plasma was stored at the same temperature 
until analysis (commenced the same day). 
2.3. Laboratory procedures 
After the removal of any chylomicrons from the 
plasma samples by ultracentrifugation [171, VLDL 
(d x 1.006 g/ml), intermediate density lipoprotein 
(IDL; d = 1.006-l .019 g/ml), low-density lipopro- 
tein (LDL; d = 1.019-l .063 g/ml) and HDL sub- 
classes 2 and 3 (HDL2, d = 1.063-1.125 g/ml; 
HDL3, d = 1.125-1.210g/ml) were isolated by fur- 
ther sequential preparative ultracentrifugation at 
40000 rev./min and 4°C in an MSE Prepspin 50 
ultracentrifuge, using a rotor with geometry 
similar to the Beckman 40.3 rotor [ 171. Centrifuga- 
tion times were 16 h, 20 h, 24 h and 40 h for flota- 
tion of VLDL, IDL, LDL, HDL2 and HDL3, 
respectively. 
Total cholesterol, glyceride and phospholipid in 
each lipoprotein fraction were measured manually 
by enzymatic procedures (Boehringer Mannheim, 
cat. no. 187313 and 16448; Wako Phospholipid 
kit, Wako Chemistry, Osaka). Total protein in 
each lipoprotein (except HDL3) was measured as in 
[ 181, using bovine serum albumin as standard. All 
analyses for each subject were carried out as one 
batch. Results were expressed as the mean values 
of triplicate determinations. 
Activities of LPL in post-heparin plasma were 
measured as in [19], using as substrate Intralipid 
into which glycerol tri-(3)oleate (Radiochemical 
Centre, Amersham) had been incorporated by the 
manufacturers (Vitrum, Sweden). 
2.4. Statistical analyses 
As the lipoprotein responses to heparin in the 5 
LPL-deficient subjects who were without 
chylomicronaemia t the start of the infusion ap- 
peared to differ in some respects from those 
observed in the 3 patients in whom chylomicro- 
naemia was still present, the changes observed in 
these two sub-groups were considered separately. 
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Statistical analyses of significance were by the 
paired Student t-test and the Wilcoxon matched- 
pairs signed rank test [20]. 
3. RESULTS 
As anticipated, the LPL-deficient subjects had 
negligible post-heparin plasma LPL activity during 
the infusions (not shown). 
As expected, VLDL triglyceride concentration 
decreased in the normal subjects during the infu- 
sion. VLDL triglyceride also decreased in the LPL- 
deficient subjects (P < 0.005 at 120 min), although 
the percentage reduction was less than that in the 
normal subjects (table 1). The VLDL phospholipid 
and protein concentrations howed no consistent 
changes in any group. 
In the normal subjects heparin also decreased 
the plasma concentrations of IDL phospholipid 
and protein (P~0.05 at 60min) (table 2). The 
LPL-deficient subjects without chylomicronaemia 
showed similar trends, whereas those with chylo- 
micronaemia showed increases in IDL phospholi- 
pid and IDL protein levels during the infusion. In 
neither group of LPL-deficient subjects, however, 
were these changes statistically significant. The 
Table 1 
Effects of intravenous infusion of heparin on plasma VLDL triglyceride concentration (mmol/l) in 5 normal subjects, 
5 LPL-deficient patients without chylomicronaemia at the time of study (no. l-5) and 3 LPL-deficient patients with 
chylomicronaemia (no. 6-8) 
Time (min) 0 30 60 90 120* 
Normal subjects 0.83 * 0.2 0.31 f 0.1 0.37 * 0.1 0.32 + 0.1 0.24 * 0.1 
(-71 Vo) 
LPL-deficiency no. 1-5 5.35 k 0.8 4.45 + 0.7 4.95 f 1.3 4.16 + 0.8 3.17 + 0.7 
(-41 o/o) 
LPL-deficiency no. 6-8 9.75 k 1.5 8.29 + 1.3 7.83 -t 1.50 6.73 + 2.2 6.94 I?Z 2.5 
(-29%) 
a Results at 120min were significantly different (P < 0.005) from those at time zero in all 3 groups (Wilcoxon test) 
Mean f SEM; Mean % changes relative to time zero are given in parentheses 
Table 2 
Effects of intravenous infusion of heparin on plasma IDL phospholipid and protein concentrations in 5 normal subjects, 
5 LPL-deficient subjects without chylomicronaemia at the time of study (no. 1-5) and 3 LPL-deficient subjects with 
chylomicronaemia (no. 6-8) 
Time 0 30 60 90 120 
Phospholipid (mg/dl) 
Normal subjects 
LPL-deficiency no. l-5 
LPL-deficiency no. 6-8 
3.4* 1.0 3.8k 1 1.0* la 1.2* 1 l.O* 0.5 
(-71 Vo) 
21 + 6 18 f 6 19 f 7 18 k 7 18 k 7 
16 k 8 26 *I18 42 + 36 34 f 28 32 k 25 
Protein @g/ml) 
Normal subjects 95.6 k 12 35.4 f 8 22.6 + 6” 31.2+ 4 
(-76%) 
LPL-deficiency no. l-5 114.8 f 29 82.4 + 23 99.0 k 32 111.62 30 
LPL-deficiency no. 6-8 84.7 + 35 109.7 f 28 131.0*44 130.3 + 45 
a P< 0.05 relative to time zero (Wilcoxon test) 
Mean k SEM mean % changes relative to time zero are given in parentheses 
52.4 + 15 
95.2 f 32 
124.0 f 72 
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Table 3 
Effects of intravenous infusion of heparin on plasma HDLz phospholipid, HDLz protein and HDLs phospholipid in 
5 normal subjects, 5 LPL-deficient subjects without chylomicronaemia at the time of study (no. 1-5) and 3 LPL- 
deficient subjects with chylomicronaemia (no. 6-8) 
Time (min) 0 30 60 90 120 
HDLz Phospholipid (mg/dl) 
Normal subjects 
LPL-deficiency no. 1-5 
LPL-deficiency no. 6-8 
HDL2 Protein &g/ml) 
Normal subjects 
LPL-deficiency no. I-5 
LPL-deficiency no. 6-8 
HDL3 Phospholipid (mg/dl) 
Normal subjects 
LPL-deficiency no. l-5 
LPL-deficiency no. 6-8 
25.7 Zk 4 25.6 + 3 
42.2 + 11 36.4 +_ 12 
41.3 * 14.3 37.0 + 13 
294 + 33 211 +29 
374 + 35 269 f 28 
215 2447 188 +- 39 
47.1 + 5 46.5 rfr 4 
39.1 f 4 44.5 Yk 7 
40.0+ 8 42.0 +- 10 
25.1 + 3 
35.8+ 9a 
(-15%) 
41.8 k 13a 
(-12%) 
295 +_41 
273 + 42a 
(-27%) 
174 + 43” 
(-19%) 
47.3 * 4 
45.4+_ 6 
43.3 + 10 
24.1 t 3 
32.4 f 10 
38.8 + 14 
262 +- 26 
260 -+- 17 
169 +- 43 
45.3 f 3 
42.3 + 8 
47.1 + 8 
a P< 0.05; b P< 0.01 relative to time zero (Wilcoxon test) 
Mean + SEM; Mean % changes relative to values at time zero are given in parentheses 
IDL cholesterol and tryglyceride levels did not 
change consistently in any group; nor were there 
any significant changes in LDL components. 
The most consistent and striking changes were 
observed in HDLz and HDL3 (table 3). In both 
sub-groups of LPL-deficient patients, the concen- 
trations of HDL2 phospholipid and HDL2 protein, 
but not of HDL2 cholesterol, decreased significant- 
ly during the infusion (PC 0.01 and P< 0.05 at 
60min, respectively). In the same subjects signifi- 
cant increases in HDLs phospholipid were observ- 
ed (P < 0.05 at 120min). No such changes were 
recorded in the HDL subfractions of normal sub- 
jects; nor did HDL2 or HDLJ cholesterol change 
significantly in this group. 
4. DISCUSSION 
This study is based on the assumptions that the 
lipoprotein changes which occur in subjects with 
23.4+ 3 
33.0 * 10” 
(-22%) 
29.7 +- 8” 
(-37%) 
269 -t 31 
235 + 8b 
(-37%) 
145 f 16b 
(-33%) 
46.3 + 3 
48.0+ 7a 
( + 23%) 
49.3 k 11” 
(+ 23%) 
complete deficiency of LPL during an infusion of 
heparin are due to release of HL into the circula- 
tion, and that those which occur in healthy subjects 
reflect effects of HL and LPL acting simultaneous- 
ly. The decrease in VLDL triglyceride concentra- 
tion which was observed during the infusions in the 
LPL-deficient subjects supported evidence from 
studies in vitro and in vivo [9] that HL can 
hydrolyse the triglyceride of VLDL, although less 
efficiently than LPL. The decreases in the 
phospholipid and protein concentrations in IDL 
observed in normal subjects could have reflected 
the activities of either or both of the enzymes. The 
similar trend which was observed in the LPL- 
deficient subjects without chylomicronaemia con- 
forms with the view [7,8] that HL may play a role 
in the hepatic catabolism of IDL, but as these 
changes were not statistically significant no confi- 
dent conclusions about IDL metabolism can be 
drawn from the present experiments. The increases 
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in IDL components observed during the first hour 
of infusion in the LPL-deficient subjects with 
chylomicronaemia may have reflected the 
catabolism of the large pool of triglyceride-rich 
precursors of IDL in this sub-group. 
The most consistent findings in LPL-deficient 
subjects were the changes in HDL subfractions. In 
all patients, both those with, and those without 
chylomicronaemia, decreases in HDLz phospho- 
lipid and HDL2 protein occurred during the infu- 
sion. Over the same period the HDL:, phospholipid 
concentration showed a reciprocal increase in these 
subjects. In contrast, normal subjects showed no 
significant changes in HDL-subfractions. These 
results are consistent with a role for hepatic lipase 
in the catabolism of HDLz or in the conversion of 
HDLz to HDL3 [14-16,211. Since there is evidence 
that the hydrolysis of VLDL triglyceride by LPL 
may contribute to the conversion of HDL3 to 
HDLz [6], the absence of any change in HDLz or 
HDL3 in the normal subjects during heparin infu- 
sion can be attributed to the opposing effects of the 
two heparin-releasable enzymes on the interconver- 
sion of HDL subclasses. The absence of any 
significant changes in HDLz and HDLs cholesterol 
in the LPL-deficient subjects, in spite of the 
changes in other HDL components, might have 
reflected a redistribution of cholesteryl ester be- 
tween the subfractions and other lipoproteins [22]. 
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